Revance Therapeutics (RVNC)

Revance Therapeutics (RVNC) Stock Price & Analysis


RVNC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$11.10 - $37.98
Previous Close$13.01
Average Volume (3M)1.77M
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)$320.00M
Total Debt (Recent Filing)$432.39M
Price to Earnings (P/E)-2.9
Nov 07, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.54
Shares Outstanding87,955,357
10 Day Avg. Volume4,033,532
30 Day Avg. Volume1,769,799
Standard Deviation0.21
Financial Highlights & Ratios
Price to Book (P/B)-14.51
Price to Sales (P/S)18.99
Price to Cash Flow (P/CF)N/A
P/FCF Ratio65.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Price Target Upside171.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Revance Therapeutics’s price range in the past 12 months?
Revance Therapeutics lowest stock price was $11.10 and its highest was $37.98 in the past 12 months.
    What is Revance Therapeutics’s market cap?
    Currently, no data Available
    When is Revance Therapeutics’s upcoming earnings report date?
    Revance Therapeutics’s upcoming earnings report date is Nov 07, 2023 which is in 42 days.
      How were Revance Therapeutics’s earnings last quarter?
      Revance Therapeutics released its earnings results on Aug 08, 2023. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.633 by $0.073.
        Is Revance Therapeutics overvalued?
        According to Wall Street analysts Revance Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Revance Therapeutics pay dividends?
          Revance Therapeutics does not currently pay dividends.
          What is Revance Therapeutics’s EPS estimate?
          Revance Therapeutics’s EPS estimate is -$0.71.
            How many shares outstanding does Revance Therapeutics have?
            Revance Therapeutics has 87,955,360 shares outstanding.
              What happened to Revance Therapeutics’s price movement after its last earnings report?
              Revance Therapeutics reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.633. Following the earnings report the stock price went down -8.049%.
                Which hedge fund is a major shareholder of Revance Therapeutics?
                Among the largest hedge funds holding Revance Therapeutics’s share is Deerfield Management Company, LP. It holds Revance Therapeutics’s shares valued at 22M.


                  Revance Therapeutics Stock Smart Score

                  The Revance Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Revance Therapeutics

                  Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.


                  Top 5 ETFs holding RVNC

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Vanguard Health Care ETF
                  Picton Mahoney Fortified Market Neutral Alternative Fund ETF
                  Picton Mahoney Fortified Long Short Alternative Fund Trust Units
                  Vanguard Russell 3000 ETF
                  Up to five ETFs with an Outperform Smart Score that hold RVNC. The ETFs are listed according to market value of RVNC within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  RAPT Therapeutics
                  Rocket Pharmaceuticals
                  Ultragenyx Pharmaceutical

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis